SIHUANPHARM：AnnualReport2019.pdf

《SIHUANPHARM：AnnualReport2019.pdf》由会员分享，可在线阅读，更多相关《SIHUANPHARM：AnnualReport2019.pdf（267页珍藏版）》请在三个皮匠报告上搜索。

1、公司簡介CORPORATE PROFILEFounded in 2001,Sihuan Pharmaceutical Holdings Group Ltd.(“Sihuan Pharmaceutical”or the“Company”),together with its subsidiaries(the“Group”)has become the largest cardio-cerebral vascular(“CCV”)drug manufacturer in Chinas prescription drug market by market share since 2007.Sihua

2、n Pharmaceutical is an integrated pharmaceutical corporation with its own production,research and development(“R&D”)and marketing capacities.The success of the Group can be attributed to its differentiated and proven sales and marketing model,extensive nationwide distribution network,diversified pro

3、duct portfolio,and strong R&D capabilities.The Group has begun its innovative drug R&D since 2008 and now possesses a well-established innovative and generic drug R&D platform,which is supported by approximately 600 R&D experts and focuses in therapeutic areas with considerable unmet clinical demand

4、.The Groups current products and R&D pipeline encompass the top five medical therapeutic areas:CCV system,central nervous system,metabolism,oncology and anti-infectives.四環醫藥控股集團有限公司（四環醫藥或 本公司，連同其附屬公司為 本集團）成立於二零零一年，自二零零七年起，成為全國最大的心腦血管（心腦血管）處方藥物市場的藥物生產商。四環醫藥為自家生產、研究與開發（研發）、營銷一體的醫藥公司。本集團的成功是由於擁有優秀的行銷模式

5、及覆蓋全國的分銷網路、具市場潛力的多元化產品組合，以及強大的研發實力。本集團於二零零八年開始投入創新藥研發，擁有約600名研發人員組成的領先的研發團隊，已建立了成熟的創新藥和仿製藥研發平台，專注於具有重大臨床需求的治療領域。本集團目前銷售產品及在研發產品線涵蓋五大醫療領域：心腦血管系統、中樞神經系統、新陳代謝、腫瘤及抗感染。目錄CONTENTS02公司資料 Corporate Information05發展里程 Milestones13財務摘要 Financial Summary15主席報告 Chairmans Statement25管理層討論及分析 Management Discussion

6、 and Analysis51董事履歷 Biographical Details of Directors59企業管治報告 Corporate Governance Report85董事會報告 Report of Directors109獨立核數師報告 Independent Auditors Report117綜合財務狀況表 Consolidated Statement of Financial Position119綜合損益及其他全面收益表 Consolidated Statement of Profit or Loss and Other Comprehensive Income121綜